Barclays Says That Udg Healthcare Public Limited Company (LON:UDG) Has GBX 875.00 Stock Target

May 17, 2018 - By Nellie Frank

UDG Healthcare plc (LON:UDG) Logo

Why Has Barclays Given Udg Healthcare Public Limited Company (LON:UDG) a GBX 875.00 Price Target

The research firm Barclays has today initiated coverage on Udg Healthcare Public Limited Company (LON:UDG) shares, with a Equal-weight rating, while setting the TP at GBX 875.00.

UDG Healthcare plc (LON:UDG) Ratings Coverage

Among 8 analysts covering UDG Healthcare PLC (LON:UDG), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. UDG Healthcare PLC has GBX 1100 highest and GBX 765 lowest target. GBX 869.50’s average target is -6.30% below currents GBX 928 stock price. UDG Healthcare PLC had 20 analyst reports since November 28, 2017 according to SRatingsIntel. N+1 Singer maintained it with “Hold” rating and GBX 813 target in Wednesday, February 7 report. The rating was maintained by Peel Hunt on Wednesday, April 4 with “Add”. The stock of UDG Healthcare plc (LON:UDG) earned “Buy” rating by Libertas Partners on Wednesday, February 7. Peel Hunt maintained the stock with “Add” rating in Tuesday, November 28 report. The stock has “Hold” rating by Stifel Nicolaus on Thursday, November 30. The stock of UDG Healthcare plc (LON:UDG) earned “Buy” rating by Peel Hunt on Tuesday, May 1. The rating was maintained by Peel Hunt with “Add” on Tuesday, December 19. The firm has “Buy” rating by Peel Hunt given on Tuesday, April 17. Numis Securities maintained the stock with “Reduce” rating in Thursday, May 17 report. As per Tuesday, January 30, the company rating was maintained by Numis Securities.

The stock increased 0.22% or GBX 2 during the last trading session, reaching GBX 928. About 847,545 shares traded. UDG Healthcare plc (LON:UDG) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and internationally. The company has market cap of 2.31 billion GBP. The firm operates through three divisions: Ashfield, Sharp, and Aquilant. It has a 32.22 P/E ratio. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.